HRT for Women in Ireland: Options, Costs & How to Access It

Hormone replacement therapy, commonly known as HRT, is a medical treatment that replaces the oestrogen and, where needed, progesterone that a woman's body produces less of during and after menopause. For many women, this hormonal decline causes symptoms that range from uncomfortable to life-disrupting, including hot flushes, night sweats, sleep disturbance, anxiety, low mood, vaginal dryness and loss of bone density. HRT addresses the root cause of these symptoms rather than simply masking them, and when prescribed appropriately it remains the most effective treatment available.

In Ireland, awareness and access to HRT have improved considerably in recent years. A growing number of GPs are confident prescribing it, specialist menopause clinics have opened in several cities, and the Government introduced a free HRT scheme as part of Budget 2025 to reduce the financial barrier to treatment. Despite this progress, many women still find the landscape confusing, unsure which type of HRT suits them, what it costs, or how to get started.

This guide is designed to help. It covers the types of HRT available in Ireland, the brands you will encounter in pharmacies, realistic costs with and without state subsidies, the evidence on benefits and risks, and the practical steps for accessing treatment through your GP or a specialist. Menopause is a natural transition, not a condition to be ashamed of, and every woman deserves clear, honest information about the treatments that can help her through it.

HRT is not a single treatment but a family of options, and the type your doctor recommends will depend on your individual circumstances. The main categories are oestrogen-only HRT, combined HRT, vaginal oestrogen and tibolone, each suited to different situations and stages of menopause.

Oestrogen-only HRT is prescribed for women who have had a hysterectomy and no longer have a uterus. Because there is no womb lining to protect, oestrogen can be given on its own without progesterone. It is available as patches, gels and tablets. Combined HRT, which pairs oestrogen with a progestogen, is the standard approach for women who still have a uterus, since the progestogen component protects the womb lining from the thickening effect of oestrogen. Combined HRT comes in two patterns: sequential, for women who are still having some periods or are in perimenopause, which produces a regular monthly withdrawal bleed, and continuous combined, for women whose periods have stopped for at least a year, which aims to avoid any bleeding.

Vaginal oestrogen is a low-dose local treatment used specifically for vaginal dryness, discomfort and urinary symptoms. It works directly where it is needed, with very little absorption into the rest of the body, and can be used alongside systemic HRT or entirely on its own. Tibolone is a synthetic hormone that has oestrogenic, progestogenic and weak androgenic effects combined in a single tablet, and suits some postmenopausal women who prefer a simpler regimen. Bioidentical HRT, which uses hormones chemically identical to those the body produces naturally, is also available in Ireland through both standard prescriptions and specialist clinics, and includes licensed products such as Utrogestan and body-identical oestradiol patches and gels.

Irish pharmacies stock a wide range of HRT products, and it helps to know what you might be offered. Oestrogen-only patches include Evorel, Estradot and FemSeven, all of which deliver oestradiol steadily through the skin and are changed once or twice a week depending on the brand. Oestrogen gels such as Oestrogel and Sandrena are applied daily to the skin and give women more flexibility in adjusting their dose. Oestrogen-only tablets include Elleste Solo and Zumenon, taken once daily by mouth.

For combined HRT, widely prescribed options include Femoston, which comes in both sequential and continuous versions, Novofem and Trisequens. These combine oestradiol with a progestogen in a single pack, simplifying the daily routine. Women who prefer to keep their oestrogen and progesterone separate often use an oestrogen patch or gel alongside Utrogestan, a micronised progesterone capsule that is body-identical and taken orally at bedtime. This combination has become increasingly popular because it allows each component to be adjusted independently.

Vaginal oestrogen products available in Ireland include Vagifem, Vagirux and Imvaggis pessaries, Blissel gel and Ovestin cream. These are applied locally and are suitable for long-term use, even in women for whom systemic HRT may not be appropriate. Tibolone is marketed as Livial. Your prescribing doctor will guide you toward the product and delivery method that best matches your symptoms, medical history and personal preferences, and it is entirely normal to try more than one option before finding the combination that works well for you.

Understanding the cost of HRT in Ireland means looking at both the pharmacy price of the medication and the broader expenses of GP visits and monitoring. Without any state subsidy, monthly pharmacy costs vary by product type. Oestrogen-only patches such as Evorel and Estradot typically cost between €25 and €45 per month, while gels like Oestrogel and Sandrena fall in the range of €25 to €40. Oestrogen-only tablets tend to be the least expensive at around €18 to €30 per month. Combined patches run from about €30 to €50 monthly, and combined tablets from roughly €25 to €55 depending on the brand and formulation.

If you are prescribed a separate progestogen such as Utrogestan alongside your oestrogen, expect to add approximately €15 to €30 per month for that component. Tibolone costs between €25 and €40 monthly, and vaginal oestrogen products range from about €20 to €35. For women using a combination of systemic HRT and vaginal oestrogen, the total unsubsidised cost could reach €50 to €80 per month before any GP fees are factored in.

However, most women will not pay these full prices. Ireland's Drugs Payment Scheme caps total monthly prescription costs at €80 per individual or family, regardless of how many items are dispensed, so even without the newer free HRT scheme your out-of-pocket medication costs are limited. Medical card holders pay a maximum of €1.50 per prescription item, up to a cap of €15 per month, making HRT very affordable for those who qualify. GP consultations, which typically cost between €50 and €70 per visit, are the main additional expense, and these are not covered by the HRT-specific scheme.

One of the most significant recent developments for Irish women is the free HRT scheme introduced as part of Budget 2025. Under this scheme, women who are registered with the Drugs Payment Scheme or who hold a medical card can have their HRT medications and dispensing fees covered at no additional cost when prescribed for menopause symptoms. The scheme applies to perimenopause, post-menopause, early menopause, premature menopause and induced menopause, covering the full range of clinical situations in which HRT is medically appropriate.

To avail of the scheme, you need a valid DPS card or medical card and a prescription from your GP or specialist. You present your prescription at your pharmacy as normal, and the HRT medication is dispensed without the usual charge. It is worth noting that the scheme covers the medication itself and the dispensing fee, but it does not cover the cost of GP consultations. You will still need to pay for your doctor's appointments unless you hold a GP visit card or medical card that covers GP care.

Registering for the DPS is straightforward and free. You can apply online through the HSE website, by post, or at your local health office, and there is no means test. Once registered, the scheme caps your monthly medication spend at €80 for all prescriptions, not just HRT, and the free HRT provision sits within this framework. If you are unsure whether you qualify or how to register, the HSE Live helpline on 1800 700 700 can guide you through the process.

The evidence supporting HRT for the management of menopausal symptoms is strong and well established. The most dramatic improvements are typically seen in vasomotor symptoms, the medical term for hot flushes and night sweats, which HRT reduces significantly in both frequency and severity for the large majority of women. Sleep quality, which is often disrupted by night sweats and hormonal fluctuations, tends to improve in tandem, and many women report meaningful reductions in anxiety, irritability and low mood within the first few months of treatment.

Beyond symptom relief, HRT offers important protective effects that extend well past the menopausal transition. Oestrogen plays a central role in maintaining bone density, and randomised trial evidence from the Women's Health Initiative shows HRT reduces the risk of osteoporotic fractures, a benefit that is particularly significant for women with early or premature menopause who face a longer period of oestrogen deficiency. There is also evidence that HRT supports muscle strength and may help preserve the lean body mass that naturally declines after menopause.

Vaginal and urogenital symptoms, including dryness, discomfort during intercourse and recurrent urinary tract infections, respond well to both systemic and local oestrogen therapy, and these benefits persist for as long as treatment continues. Current medical consensus, reflected in guidelines from bodies including the British Menopause Society and the Irish College of General Practitioners, is clear: for most women under 60, or those starting within ten years of menopause onset, the benefits of HRT outweigh the risks, provided there are no specific contraindications. This is not a fringe position but the mainstream evidence-based view.

Any responsible discussion of HRT must address the risks honestly, and the picture is considerably more reassuring than many women have been led to believe. The most widely discussed concern is breast cancer risk. The current evidence shows that combined HRT, which includes both oestrogen and a progestogen, is associated with a small increase in risk, roughly five additional cases of breast cancer per one thousand women over five years of use. To put that in context, this is a similar magnitude of increased risk to that associated with being overweight, drinking two or more units of alcohol per day, or being physically inactive. Oestrogen-only HRT shows little or no increase in breast cancer risk.

The risk of blood clots, including deep vein thrombosis, is slightly increased with HRT taken in tablet form, because oral oestrogen passes through the liver and affects clotting factors. However, transdermal preparations such as patches and gels bypass the liver and do not carry this additional clot risk, which is one of the reasons many prescribers now favour them, particularly for women who are overweight, have a history of migraines or carry other clot risk factors.

Concerns about heart disease have also been largely put to rest by more recent research. When HRT is started within ten years of menopause or before the age of 60, it does not increase cardiovascular risk and may in fact offer some protective benefit. HRT does not increase the risk of type 2 diabetes. As with any medication, the decision to start HRT should be made on an individual basis with your doctor, weighing your personal symptoms, health history and risk factors, but the outdated narrative that HRT is broadly dangerous does not reflect what the evidence actually shows.

The most common and straightforward route to HRT in Ireland is through your GP. Make an appointment specifically to discuss your menopausal symptoms, and go prepared to describe what you are experiencing, when it started, how it affects your daily life, and any relevant medical history including family history of breast cancer or blood clots. Most GPs are now comfortable initiating HRT for straightforward cases and can prescribe it directly without a specialist referral, though they may refer you to an endocrinologist or menopause specialist for more complex situations.

For women who prefer a specialist-led approach or who want access to more tailored regimens including bioidentical options, dedicated menopause clinics have become increasingly available in Ireland. Services such as The Menopause Hub Ireland offer comprehensive assessments, hormone testing and individualised treatment plans. These clinics are typically private and charge consultation fees, but they bring focused expertise and often more time per appointment than a busy GP surgery can offer.

Online consultations have also made HRT more accessible, particularly for women in rural areas or those who find it difficult to attend in person. Services such as DocOnCall offer video consultations with registered Irish doctors from around €55, and can prescribe HRT where clinically appropriate, with prescriptions sent directly to your pharmacy. If you are unsure where to start or what questions to ask, the HSE Live helpline on 1800 700 700 provides free, confidential guidance. Whatever route you choose, the key is to have the conversation with a qualified doctor rather than trying to navigate treatment decisions alone or sourcing hormones without medical supervision.

Knowing what to expect from your first HRT appointment can make the process less daunting. Your doctor will ask about your symptoms in detail, including their severity, duration and impact on your quality of life. They will take a full medical history covering any personal or family history of breast cancer, blood clots, stroke, heart disease and liver problems, as these may influence the type of HRT recommended or whether additional caution is needed.

In most cases, blood tests are not required to diagnose menopause in women over 45 with typical symptoms, as the diagnosis is made clinically. However, your doctor may request blood tests if you are under 45, if there is diagnostic uncertainty, or to check baseline health markers such as thyroid function, cholesterol and blood count. A blood pressure check and, where appropriate, a discussion of breast screening and cervical screening are also part of a thorough assessment.

Once a decision is made to start HRT, your doctor will explain the options, recommend a starting regimen, and arrange a follow-up appointment, usually at around three months, to review how you are responding. It is entirely normal for the first prescription to be adjusted. Some women respond well immediately, while others need a change of dose, delivery method or product before finding what works best. Be patient with the process, keep a note of your symptoms, and communicate openly with your doctor about what is and is not improving. HRT is not a one-size-fits-all treatment, and the willingness to fine-tune it is a hallmark of good care.